comparing glp-1 agonists for Weight Loss: A Side-by-Side Comparison What Are GLP-1 Agonists For
Description
Patients taking tirzepatide 10 mg achieved an average of 19.5% weight loss, and patients taking tirzepatide 15 mg achieved an average of 20.9% weight loss
Orlistat is generally the least favored option due to its side effect profile, and its benefit is reduced if an individual is already following a low-fat diet, although gastrointestinal side effects may persist
An increased risk of diabetic retinopathy has been reported in a clinical trial of semaglutide, which has been hypothesised to be related to the magnitude and rapidity of glucose lowering [61]
What the Research Actually Supports The clinical trials that led to FDA approval of semaglutide and tirzepatide used the standard titration schedules
2024;11:e2405987
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
